Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celltrion Invests In UK’s Iksuda

Takes Controlling Stake In ADC Specialist Through $47m Financing Round

Executive Summary

Celltrion has taken a controlling stake in ADC specialist Iksuda as part of a $47m financing round that has just been closed by the UK-based company.

You may also be interested in...



Celltrion Strikes $278m Deal With Takeda

Celltrion has bought a portfolio of selected products in the Asia-Pacific region from Takeda, marking a foray into small-molecule drugs.

Amneal Takes A Step Forward On Biosimilars

The FDA’s acceptance of Amneal’s filing for bevacizumab brings the company a step closer to its goal of launching a US biosimilar every year to 2023.

EU Industry Sets Out Priorities In Structured Dialog

As part of a “structured dialog” initiated with pharmaceutical industry stakeholders by the European Commission, local off-patent industry association Medicines for Europe has set out the key reforms needed to bolster the sector.

Topics

Related Companies

UsernamePublicRestriction

Register

GB150979

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel